|
|
Article: NicOx's Nitric Oxide-Releasing Steroid, NCX 1022, Shows Promising Clinical Results in Skin Blanching.
- Article from:
- PR Newswire
- Article date:
- May 14, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SOPHIA ANTIPOLIS, France, May 14 /PRNewswire/ --
NicOx S.A. (Nouveau Marche: NICOX) announced that a topical formulation of NCX 1022 showed promising results in a Phase I clinical dermatology study evaluating local skin vasoconstriction, (a human skin blanching assay approved by the FDA). NCX 1022 is a nitric oxide-releasing derivative of the steroid, hydrocortisone, in development for the treatment of psoriasis which is a chronic skin condition in which scaly pink patches form on the elbows, knees, scalp, and other parts of the body.
The rationale of this study was to test the postulate that nitric oxide progressive release from a NO-steroid can ...